← Back to Search

Free Radical Scavenger

MT-1186 for Lou Gehrig's Disease

Phase 3
Waitlist Available
Research Sponsored by Mitsubishi Tanabe Pharma America Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to week 96
Awards & highlights

Study Summary

This trial is testing a drug to treat ALS, and is assessing its long-term safety and tolerability.

Eligible Conditions
  • Lou Gehrig's Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to week 96
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to week 96 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Safety and tolerability as measured by incidence of Adverse events (AEs), adverse drug reactions (ADRs), and treatment-emergent adverse events ([TEAEs])
Other outcome measures
Change from baseline to week 96
Time (days) to death, tracheostomy, or permanent assisted mechanical ventilation (>= 23 hours/day)

Side effects data

From 2021 Phase 3 trial • 185 Patients • NCT04165824
22%
Fall
21%
Muscular weakness
18%
Constipation
10%
Back pain
9%
Dyspnoea
9%
Insomnia
9%
Dysphagia
8%
Fatigue
8%
Contusion
7%
Headache
7%
Muscle spasms
6%
Amyotrophic lateral sclerosis
6%
Salivary hypersecretion
5%
Musculoskeletal pain
5%
Rash
5%
Depression
3%
Respiratory failure
2%
Pneumonia
1%
Oxygen saturation decreased
1%
Cellulitis
1%
Upper Respiratory Tract Infection
1%
Covid-19
1%
Acute respiratory failure
1%
Pelvic pain
1%
Gait disturbance
1%
Dehydration
1%
Hyponatraemia
1%
Diabetic ketoacidosis
1%
Feeding disorder
1%
Completed suicide
1%
Pleural effusion
1%
Supraventricular tachycardia
1%
Muscle spasticity
1%
Chronic respiratory failure
1%
Pain
1%
Atrial fibrillation
1%
Patella fracture
1%
Restrictive pulmonary disease
1%
Lung disorder
1%
Lower limb fracture
1%
Weight decreased
1%
Gastrostomy
100%
80%
60%
40%
20%
0%
Study treatment Arm
MT-1186

Trial Design

1Treatment groups
Experimental Treatment
Group I: MT-1186Experimental Treatment1 Intervention
Oral Edaravone administered once daily for 10 days out of 14, followed by a 14-day drug- free period
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MT-1186
2021
Completed Phase 3
~600

Find a Location

Who is running the clinical trial?

Mitsubishi Tanabe Pharma America Inc.Lead Sponsor
26 Previous Clinical Trials
3,028 Total Patients Enrolled
Mitsubishi Tanabe Pharma Development America, Inc.Lead Sponsor
21 Previous Clinical Trials
2,358 Total Patients Enrolled
Head of Medical ScienceStudy DirectorMitsubishi Tanabe Pharma America Inc.
17 Previous Clinical Trials
2,212 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any other treatments like this that have been tried before?

"MT-1186 has undergone 9 clinical trials in 94 cities across 10 countries. The first trial was sponsored by Mitsubishi Tanabe Pharma Development America, Inc. in 2020 and completed Phase 3 drug approval that year. A total of 140 participants were involved. Since then, 26 more trials have been completed."

Answered by AI

What is the American federal government's opinion of MT-1186?

"Since this is a Phase 3 trial, there is available data that suggests MT-1186 is safe as well as evidence from multiple rounds of testing that support this claim."

Answered by AI

Do we have any prior data to refer to regarding MT-1186?

"MT-1186 was first investigated in 2020 at the Walter Mackenzie Health Sciences Centre (WCM) in Alberta. So far, there have been 26 completed clinical trials. 9 more are ongoing, with many taking place in Milwaukee, Wisconsin."

Answered by AI
~29 spots leftby Mar 2025